AFP and hepatocellular carcinoma: Surveillance programmes to detect new or recurrent HCC in at-risk individuals currently involve using ultrasound (US) and an alpha feto-protein (AFP) measurement and is supported by variable quality evidence of possible mortality benefit [5,6].